More industry-friendly DXM bill introduced
This article was originally published in The Tan Sheet
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, introduce the Dextromethorphan Abuse Reduction Act June 25 to set an age limit on purchases of the OTC products containing the ingredient. S. 1383, which was referred to the Judiciary Committee, would ban retail sales of DXM OTC products to consumers under 18 years. The legislation differs from a DXM bill then-Sen. Joe Biden introduced in the previous Congress, the Consumer Healthcare Products Association says (1"The Tan Sheet" Sept. 15, 2008). In a change CHPA lobbied for, S. 1383 does not require adding raw DXM to the Controlled Substances Act, the trade group said June 26. Classifying raw DXM as a controlled substance would unnecessarily increase drug firms' regulatory burdens and is not needed to curb abuse of the cough medicine ingredient, according to CHPA
You may also be interested in...
Yamila Abraham faces prison time and fines for allegedly selling dextromethorphan hydrobromide as a misbranded "herbal alternative" to street drugs. The U.S. district attorney for Nevada alleges said Sept. 21 Abraham sold the misbranded drug as "Snurf," leading to four 10th graders being hospitalized in September 2008. Police suspected the pills contained DXM, an active ingredient in OTC cough suppressants. Sen. Chuck Grassley, R-Iowa, said the hospitalization bolstered the need for legislation to restrict bulk DXM sales. His Dextromethorphan Abuse Reduction Act would set a minimum age for people to purchase DXM products (1"The Tan Sheet" June 29, 2009)
A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.